Allen, Jennifer D.
Abuelezam, Nadia N.
Rose, Raviv
Isakoff, Katelin
Zimet, Gregory
Fontenot, Holly B.
Funding for this research was provided by:
Office of the Vice Provost for Research, Tufts University
Article History
Received: 4 January 2024
Accepted: 29 April 2024
First Online: 8 August 2024
Declarations
:
: All study protocols and procedures were approved by the Institutional Review Board at Tufts University (protocol number: 00001954). All study activities were carried out in accordance with the relevant guidelines and regulations of the Declaration of Helsinki. Informed consent was obtained from all participants.
: Study consent procedures were conducted electronically before the start of the survey (by clicking on a box indicating consent box).
: Not applicable.
: JDA, RR, KI, NA have no competing interests. Outside of the current work, Gregory Zimet has received consulting fees from Merck for work on HPV vaccination and has served on external advisory committees for Moderna (COVID-19 vaccination) and Pfizer (meningococcal vaccination), and through Indiana University, has also received investigator-initiated grant funding from Merck related to HPV vaccination. Dr. Fontenot has also received investigator-initiated grant funding from Merck regarding adolescent vaccination. Drs. Fontenot and Zimet confirm that their funding source(s) have had no involvement in the conduct of this work. No other authors have conflicts of interest to report, nor competing financial interests.